Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AJ Complement inhibitors
L04AJ06 Zilucoplan
D12356 Zilucoplan sodium (JAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Complement Inhibitors
Zilucoplan
D12356 Zilucoplan sodium (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D12356 Zilucoplan sodium (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02980 CYP4F2 substrate
DG03224 Zilucoplan
D12356 Zilucoplan sodium
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Peptidase inhibitors
alpha2M family
C5
D12356 Zilucoplan sodium (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12356
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12356
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12356
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12356
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12356
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D12356
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02980 CYP4F2 substrate
DG03224 Zilucoplan
